CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND EVERY
PAPER REFERRED TO THEREIN AS BEING ENCLOSED
IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE
AS FIRST CLASS MAIL, POSTAGE PREPAID, IN
AN ENVELOPE ADDRESSED TO: COMMISSIONER OF

#7 14Cooper 8.5.30 17880K

AN ENVELOPE ADDRESSED TO: COMMISSIONER OF PATENTS & TADEMARKS, WASHINGTON, DC 20231, COMMISSIONER OF PATENTS & TADEMARKS, WASHINGTON, COMMISSIONER &

0161፫፫9490-US3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICI

In re Application of:

Michael L. MARIN and Ralph MARIN

Serial No.: 09/504,732

Group Art Unit: 3731

Filed: February 16, 2000

Examiner: W. Lewis

For: METHOD FOR ENDOLUMINALLY EXCLUDING AN AORTIC ANEURYSM

(As Amendmed)

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION

Hon. Commissioner of Patents and Trademarks Washington, DC 20231 July 19, 2000

Sir:

The undersigned is an attorney of record in the above-identified patent application, of which Teramed, Inc., located at 6655 Wedgewood Road, Suite 150, Maple Grove, Minnesota 55311, is the owner of the entire right, title, and interest in the above-identified patent application by assignment from the inventors.

07/25/2000 ZMONTES 00000100 09504732

01 FC:148

110.00 OP /

The assignment document is dated October 17, 1994 and was recorded by the U.S. Patent and Trademark Office on October 18, 1994, at Reel 7192, Frame 0144. A change of name from Endovascular Systems, Inc. to Teramed, Inc. is being made of record to the Assignment Branch together with the filing of this paper.

Teramed, Inc. hereby disclaims, except as provided below, the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of U.S. patent No. 6,039,749 or 5,443,477 and hereby agrees that the granted patent shall be enforceable only during such period that the legal title to said granted patent shall be the same as the legal title to any U.S. Patent granted on the above-identified patent application, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

The statutory fee of \$110.00 for a disclaimer is enclosed.

Teramed, Inc. does not disclaim any terminal part of any patent granted on the above-identified U.S. patent application prior to the expiration date of the full statutory term of U.S. Patent No. 6,039,749 or 5,443,477, in the event that either U.S. Patent No. 6,039,749 or 5,443,477 later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid;

1.

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a); or

has all claims cancelled by a reexamination certificate.

Respectfully submitted,

David Leason

Reg. No. 36,195

Attorney For Applicant(s)

DARBY & DARBY P.C. 805 Third Avenue New York, NY 10022 (212) 527-7700